Jacobi Capital Management LLC Purchases 2,376 Shares of SPDR S&P Biotech (NYSEARCA:XBI)

Jacobi Capital Management LLC boosted its stake in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 99.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,776 shares of the exchange traded fund’s stock after buying an additional 2,376 shares during the quarter. Jacobi Capital Management LLC’s holdings in SPDR S&P Biotech were worth $368,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in XBI. Russell Investments Group Ltd. raised its holdings in shares of SPDR S&P Biotech by 61.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 49,141 shares of the exchange traded fund’s stock valued at $3,792,000 after purchasing an additional 18,746 shares in the last quarter. Bray Capital Advisors raised its stake in shares of SPDR S&P Biotech by 120.3% during the 2nd quarter. Bray Capital Advisors now owns 15,610 shares of the exchange traded fund’s stock worth $1,205,000 after acquiring an additional 8,525 shares in the last quarter. Boston Advisors LLC bought a new position in shares of SPDR S&P Biotech during the 2nd quarter worth approximately $213,000. Meridian Wealth Management LLC bought a new position in shares of SPDR S&P Biotech during the 2nd quarter worth approximately $432,000. Finally, FineMark National Bank & Trust raised its stake in shares of SPDR S&P Biotech by 7.4% during the 2nd quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock worth $402,000 after acquiring an additional 360 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/jacobi-capital-management-llc-acquires-2376-shares-of-spdr-sp-biotech-xbi/1603744.html.

SPDR S&P Biotech (NYSEARCA:XBI) traded up 0.20% during mid-day trading on Friday, reaching $83.32. 1,037,215 shares of the company’s stock traded hands. SPDR S&P Biotech has a 52 week low of $53.15 and a 52 week high of $84.90. The stock’s 50 day moving average is $79.32 and its 200-day moving average is $73.90.

SPDR S&P Biotech Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with our FREE daily email newsletter.

 


Latest News

New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw


Leave a Reply

 
© 2006-2017 BBNS.